Hetrombopag

Drug Profile

Hetrombopag

Alternative Names: Hetrombopag olamine; SHR 8735 olamine

Latest Information Update: 11 May 2016

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Idiopathic thrombocytopenic purpura

Most Recent Events

  • 11 May 2016 Chemical structure information added
  • 01 Nov 2015 Jiangsu HengRui Medicine initiates enrolment in a phase I trial in Idiopathic thrombocytopenic purpura in China (PO) NCT02614846)
  • 01 Apr 2014 Jiangsu HengRui Medicine completes a phase I trial in Healthy volunteers in China (NCT02409394)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top